Algernon Pharmaceuticals Inc.

CNSX:AGN Stock Report

Market Cap: CA$2.2m

Algernon Pharmaceuticals Valuation

Is AGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AGN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AGN's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for AGN?

Key metric: As AGN is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for AGN. This is calculated by dividing AGN's market cap by their current book value.
What is AGN's PB Ratio?
PB Ratio1.1x
BookCA$1.96m
Market CapCA$2.18m

Price to Book Ratio vs Peers

How does AGN's PB Ratio compare to its peers?

The above table shows the PB ratio for AGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.1x
WIB West Island Brands
0.7xn/aCA$2.0m
TILT TILT Holdings
0.3x56.0%CA$3.9m
OMIC Optima Medical Innovations
0.5xn/aCA$2.1m
CFT Craftport Cannabis
2.9xn/aCA$2.7m
AGN Algernon Pharmaceuticals
1.1xn/aCA$2.2m

Price-To-Book vs Peers: AGN is expensive based on its Price-To-Book Ratio (1.1x) compared to the peer average (0.3x).


Price to Book Ratio vs Industry

How does AGN's PB Ratio compare vs other companies in the CA Pharmaceuticals Industry?

10 CompaniesPrice / BookEstimated GrowthMarket Cap
AYR.A Ayr Wellness
0.1x40.6%US$79.88m
BZAM BZAM
0.08xn/aUS$4.88m
AVNT Avant Brands
0.1xn/aUS$4.17m
CPTR Captor Capital
0.07xn/aUS$1.97m
AGN 1.1xIndustry Avg. 1.1xNo. of Companies11PB00.61.21.82.43+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: AGN is expensive based on its Price-To-Book Ratio (1.1x) compared to the Canadian Pharmaceuticals industry average (1.1x).


Price to Book Ratio vs Fair Ratio

What is AGN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AGN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate AGN's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies